Jane Street’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-35,842
| Closed | -$1.35M | – | 10863 |
|
|
2021
Q1 | $1.35M | Sell |
35,842
-24,785
| -41% | -$618K | ﹤0.01% | 4838 |
|
|
2020
Q4 | $1.03M | Buy |
60,627
+38,813
| +178% | +$486K | ﹤0.01% | 4604 |
|
|
2020
Q3 | $103K | Sell |
21,814
-4,654
| -18% | -$23.6K | ﹤0.01% | 6743 |
|
|
2020
Q2 | $161K | Buy |
+26,468
| New | +$109K | ﹤0.01% | 6506 |
|
|
2019
Q3 | – | Sell |
-51,544
| Closed | -$311K | – | 6043 |
|
|
2019
Q2 | $311K | Buy |
+51,544
| New | +$493K | ﹤0.01% | 4151 |
|
|
2019
Q1 | – | Sell |
-11,870
| Closed | -$110K | – | 5915 |
|
|
2018
Q4 | $110K | Buy |
+11,870
| New | +$141K | ﹤0.01% | 4611 |
|
|
2017
Q3 | – | Sell |
-6,677
| Closed | -$201K | – | 5273 |
|
|
2017
Q2 | $201K | Buy |
+6,677
| New | +$208K | ﹤0.01% | 4032 |
|
|
2016
Q2 | – | Sell |
-13,488
| Closed | -$548K | – | 4786 |
|
|
2016
Q1 | $548K | Buy |
+13,488
| New | +$464K | ﹤0.01% | 2504 |
|
|
2015
Q3 | – | Sell |
-11,939
| Closed | -$297K | – | 4351 |
|
|
2015
Q2 | $297K | Buy |
+11,939
| New | +$266K | ﹤0.01% | 2832 |
|
Jane Street's FPRX Position: Q2 2021 in Review
Jane Street sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 35,842 shares — an estimated $1.35M sold.
Jane Street first reported a position in FPRX in Q2 2015 and held it in 9 quarters. The position peaked at $1.35M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Jane Street reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Jane Street sold 35,842 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $1.35M.
- Jane Street first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
- Jane Street's Five Prime Therapeutics, Inc. position peaked at $1.35M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Jane Street's 13F filing for Q2 2021, filed 16 Aug 2021.